Search results for "Glucan"

showing 10 items of 131 documents

Skeletal alterations, developmental delay and new mutations in juvenile-onset Pompe disease.

2018

Abstract Pompe disease is an autosomal recessive disorder caused by a deficiency of acid α-glucosidase. In addition to the severe infantile form with cardiac involvement, late-onset variants can affect older children, adolescents (aged >1 year old) or adults. Patients with juvenile (a subgroup of late-onset type) Pompe disease typically do not have cardiac alterations e.g. hypertrophic cardiomyopathy, and the diagnosis is often difficult because it can clinically resemble myriad other neuromuscular disorders. A high level of clinical suspicion is necessary for a timely and accurate diagnosis. We describe 3 interesting cases of patients with juvenile-onset Pompe disease who presented some un…

0301 basic medicineMalePediatricsmedicine.medical_specialtyAdolescentDevelopmental DisabilitiesDisease03 medical and health sciences0302 clinical medicinemedicineJuvenileHumansMuscle SkeletalGenetics (clinical)business.industryGlycogen Storage Disease Type IIGenetic variantsalpha-Glucosidases030104 developmental biologyJuvenile onsetNeurologyPediatrics Perinatology and Child HealthMutationNeurology (clinical)Glucan 14-alpha-Glucosidasebusiness030217 neurology & neurosurgeryNeuromuscular disorders : NMD
researchProduct

(1,3)-β-d-Glucan-based antifungal treatment in critically ill adults at high risk of candidaemia: an observational study.

2016

OBJECTIVES To determine the effects of a strategy that uses serum (1,3)-β-d-glucan (BDG) results for antifungal treatment of ICU patients at high risk of invasive candidiasis. PATIENTS AND METHODS Adult patients admitted to the ICU from January 2012 to June 2014 were included if they exhibited sepsis at the time of BDG testing and they met Candida score components ≥3. A retrospective analysis of collected data was performed. RESULTS In total, 198 patients were studied. Of 63 BDG-positive patients, 47 with candidaemia and 16 with probable Candida infection, all [31.8% (63/198)] received antifungal therapy. Of 135 BDG-negative patients, 110 [55.5% (110/198)] did not receive antifungal therapy…

0301 basic medicineMicrobiology (medical)AntifungalAdultMalemedicine.medical_specialtyAntifungal AgentsAntigens Fungalbeta-GlucansLetterAdolescentMedicine (all); Pharmacology; Infectious Diseases; Pharmacology (medical)medicine.drug_classCritical Illness030106 microbiologyAntifungal drugSettore MED/17 - MALATTIE INFETTIVESettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICAlaw.inventionSepsis03 medical and health sciencesYoung AdultlawInternal medicineSepsismedicineHumansPharmacology (medical)Candidiasis InvasiveMedical prescriptionYoung adultCandidaAgedRetrospective StudiesPharmacologyAged 80 and overbusiness.industryMedicine (all)Retrospective cohort studyMiddle Agedmedicine.diseaseIntensive care unitSurgeryInfectious DiseasesObservational studyFemaleProteoglycansbusinessThe Journal of antimicrobial chemotherapy
researchProduct

Assessing the biological activity of the glucan phosphatase laforin

2016

Glucan phosphatases are a recently discovered family of enzymes that dephosphorylate either starch or glycogen and are essential for proper starch metabolism in plants and glycogen metabolism in humans. Mutations in the gene encoding the only human glucan phosphatase, laforin, result in the fatal, neurodegenerative, epilepsy known as Lafora disease. Here, we describe phosphatase assays to assess both generic laforin phosphatase activity and laforin's unique glycogen phosphatase activity.

0301 basic medicinePhosphataseLafora diseaseArticleSubstrate SpecificityNitrophenols03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOrganophosphorus CompoundsDual-specificity phosphatasemedicineHumansGlucanEnzyme Assayschemistry.chemical_classificationGlycogenbiologyfood and beveragesBiological activitymedicine.diseaseFluoresceinsProtein Tyrosine Phosphatases Non-Receptor030104 developmental biologyEnzymechemistryBiochemistryLafora Diseasebiology.proteinLaforin030217 neurology & neurosurgeryGlycogen
researchProduct

Quality characteristics and in vitro digestibility study of barley flour enriched ditalini pasta

2016

A ditalini pasta with a mixture of durum wheat and beta-glucan enriched barley flour (BF) (60/40%, w/w) was found to have a final content of 5% beta-glucan (BF-ditalini). Main quality parameters of BF-ditalini, water uptake and starch-protein texture, were comparable with those of 100% durum wheat ditalini (control). After in vitro simulated intestinal digestion, the content of beta-glucan in the post intestinal (PI) supernatant of BF-ditalini processed with its cooking water (soup) was six fold higher than that of pasta asciutta. BF-ditalini soup, but not pasta asciutta, strongly delayed the hydrolysis of the starch, without difference of viscosity between PI supernatant and control. PI su…

0301 basic medicineStarch03 medical and health sciencesHydrolysischemistry.chemical_compound0404 agricultural biotechnologyBarley flour(1/3-1/4) b-glucanSettore BIO/10 - BiochimicaPhenolFunctional food (1/3-1/4) b-glucan Barley flour In vitro digestion Antioxidant capacityFood scienceQuality characteristics030109 nutrition & dieteticsChemistryFunctional foodBarley flourIn vitro digestionfood and beverages04 agricultural and veterinary sciencesIntestinal digestionSettore CHIM/08 - Chimica Farmaceutica040401 food scienceIn vitroAntioxidant capacityAntioxidant capacityFunctional food; (1/3-1/4) b-glucan; Barley flour; In vitro digestion; Antioxidant capacityFood Science
researchProduct

Beta-glucans and cancer: The influence of inflammation and gut peptide

2017

Dietary β-glucans are soluble fibers with potentially health-promoting effects. Gut peptides are important signals in the regulation of energy and glucose homeostasis. This article reviews the effects of different enriched β-glucan food consumption on immune responses, inflammation, gut hormone and cancer. Gut hormones are influenced by enriched β-glucan food consumption and levels of such peptide as YY, ghrelin, glucagon-like peptide 1 and 2 in humans influence serum glucose concentration as well as innate and adaptive immunity. Cancer cell development is also regulated by obesity and glucose dishomeostasy that are influenced by β-glucan food consumption that in turn regulated gut hormones.

0301 basic medicinemedicine.medical_specialtybeta-GlucansInflammationbeta-Glucan03 medical and health sciences0302 clinical medicineImmune systemGlucagon-Like Peptide 1Functional FoodNeoplasmsInternal medicineβ-GlucanDrug DiscoveryGlucagon-Like Peptide 2medicineAnimalsHumansInsulinGlucose homeostasisPeptide YYCancerInflammationPharmacologyPYYAnimalChemistryDrug Discovery3003 Pharmaceutical Sciencedigestive oral and skin physiologyOrganic ChemistryGeneral MedicineGlucagon-like peptide-2Glucagon-like peptide-1GhrelinGlucose030104 developmental biologyEndocrinology030220 oncology & carcinogenesisPeptide YYNeoplasmGhrelinmedicine.symptomGLP-1GLP-2HumanHormoneEuropean Journal of Medicinal Chemistry
researchProduct

A pilot study of laparoscopic adhesion prophylaxis after myomectomy with a copolymer designed for endoscopic application.

2009

Abstract Study Objective To assess the laparoscopic handling and safety of D,L-polylactide-e-caprolactone-trimethylene carbonate (PCT) copolymer after myomectomy and compare it with icodextrin. In contrast to previously developed solid barriers, the material has rationally designed properties that are advantageous for convenient laparoscopic application. Design A randomized, single-blinded clinical study (Canadian Task Force Classification I). Setting Single-center study in a German University Hospital. Patients Thirty patients who underwent laparoscopic myomectomy were enrolled. Interventions After laparoscopic myomectomy and subsequent reconstruction of the uterus with interrupted sutures…

Adultmedicine.medical_specialtyRandomizationPolyestersAdhesion (medicine)Pilot ProjectsTissue AdhesionsPeritoneal DiseasesIcodextrinIcodextrinmedicineHumansSingle-Blind MethodAdverse effectLaparoscopyGlucansmedicine.diagnostic_testLeiomyomabusiness.industryPelvic painSuture TechniquesObstetrics and GynecologyAdhesion barriermedicine.diseaseSurgerymedicine.anatomical_structureGlucoseTreatment OutcomeUterine NeoplasmsAbdomenFemaleLaparoscopymedicine.symptombusinessFollow-Up StudiesJournal of minimally invasive gynecology
researchProduct

Formation of a new cell wall by protoplasts of Candida albicans: effect of papulacandin B, tunicamycin and Nikkomycin.

1987

SUMMARY: Incorporation of polysaccharides into the walls of regenerating protoplasts of Candida albicans was followed in the presence of papulacandin B, tunicamycin and nikkomycin. With the first drug, chitin was incorporated normally whereas incorporation of glucans and mannoproteins was significantly decreased. Tunicamycin decreased incorporation of all wall polymers when added at the beginning of the regeneration process but blocked only mannan and alkali-insoluble glucan incorporation when added after 5 h. Nikkomycin inhibited chitin synthesis, and the walls formed by the protoplasts were enriched in alkali-soluble glucan. Pulse-chase experiments suggested that a precursor-product relat…

Antifungal AgentsPapulacandin Bmacromolecular substancesBiologyPolysaccharideMicrobiologyCell wallchemistry.chemical_compoundAgglutininChitinCell WallCandida albicansGlucanMannanchemistry.chemical_classificationProtoplastsTunicamycinfungiPolysaccharides BacterialTunicamycinAnti-Bacterial Agentscarbohydrates (lipids)Microscopy ElectronAminoglycosideschemistryBiochemistryJournal of general microbiology
researchProduct

Incorporation of mannoproteins into the walls of aculeacin A-treated yeast cells

1986

Inhibition of the synthesis of alkali-insoluble glucan by aculeacin A in Saccharomyces cerevisiae cells caused a decrease in the incorporation of a high molecular weight heterogeneous mannoprotein material and of a 33,000 mannoprotein into the wall network. This was concomitant with the excretion of the latter molecule into the growth medium. Regenerating yeast protoplasts liberated considerable amounts of the heterogeneous material to the medium independently of the presence of aculeacin. The protoplast walls did lack this component and contained only minor amounts of the 33,000 molecule, which was also completely absent from walls of aculeacin-treated protoplasts. Considerable levels of t…

Antifungal AgentsSaccharomyces cerevisiaeCellPopulationSaccharomyces cerevisiaePeptides CyclicBiochemistryMicrobiologyFungal ProteinsCell wallchemistry.chemical_compoundCell WallGeneticsmedicineeducationGlucansMolecular BiologyGlycoproteinsGlucanchemistry.chemical_classificationGrowth mediumeducation.field_of_studyMembrane GlycoproteinsbiologyProtoplastsGeneral MedicineProtoplastbiology.organism_classificationYeastcarbohydrates (lipids)medicine.anatomical_structureBiochemistrychemistryImmunologic TechniquesCarbohydrate MetabolismElectrophoresis Polyacrylamide GelArchives of Microbiology
researchProduct

A kinetic study on the regeneration ofCandida albicansprotoplasts in the presence of cell wall synthesis inhibitors

1993

Aculeacin A and papulacandin B block cell wall regeneration in Candida albicans protoplasts at an intermediate step in which the protoplasts have not yet synthesized the rigid structure of the cell wall and are therefore still osmotically sensitive. In the presence of the antibiotics, total synthesis of glucan is not significantly lowered with respect to control cells, although most of it appears either in the culture medium or in the regenerating wall as alkali-soluble glucan. Thus, it is proposed that echinocandins (such as aculeacin A) and papulacandins may not inhibit glucan synthesis per se but instead inhibit its incorporation into the supramolecular organization of the cell wall.

Antifungal AgentsTime FactorsEchinocandinPapulacandin BBiologyPeptides CyclicMicrobiologyCell wallchemistry.chemical_compoundCell WallCandida albicansGeneticsmedicineCandida albicansMolecular BiologyGlucanchemistry.chemical_classificationProtoplastsProtoplastbiology.organism_classificationYeastAnti-Bacterial AgentsKineticsAminoglycosideschemistryBiochemistryEchinocandinsmedicine.drugFEMS Microbiology Letters
researchProduct

A role for the MAP kinase gene MKC1 in cell wall construction and morphological transitions in Candida albicans.

1998

The Candida albicans MKC1 gene encodes a mitogen-activated protein (MAP) kinase, which has been cloned by complementation of the lytic phenotype associated with Saccharomyces cerevisiae slt2 (mpk1) mutants. In this work, the physiological role of this MAP kinase in the pathogenic fungus C. albicans was characterized and a role for MKC1 in the biogenesis of the cell wall suggested based on the following criteria. First, C. albicans mkc1Δ/mkc1Δ strains displayed alterations in their cell surfaces under specific conditions as evidenced by scanning electron microscopy. Second, an increase in specific cell wall epitopes (O-glycosylated mannoprotein) was shown by confocal microscopy in mkc1Δ/mkc1…

Antifungal AgentsTranscription GeneticSaccharomyces cerevisiaeMutantMAP Kinase Kinase 2MAP Kinase Kinase 1ChitinSaccharomyces cerevisiaeProtein Serine-Threonine KinasesMicrobiologyGene Expression Regulation EnzymologicFungal ProteinsPseudohyphal growthCell WallGene Expression Regulation FungalCandida albicansCandida albicansDNA FungalFluorescent Antibody Technique IndirectGlucansProtein Kinase CMitogen-Activated Protein Kinase KinasesRecombination GeneticMembrane GlycoproteinsMicroscopy ConfocalbiologyKinaseProtein-Tyrosine Kinasesbiology.organism_classificationFlow Cytometrybeta-GalactosidaseCorpus albicansComplementationMicroscopy ElectronBiochemistryMitogen-activated protein kinaseCalcium-Calmodulin-Dependent Protein Kinasesbiology.proteinMicroscopy Electron ScanningMitogen-Activated Protein KinasesPlasmidsMicrobiology (Reading, England)
researchProduct